QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,066 signal articles · 538 in last 24h · 103,602 total before filter · latest 18m ago
538last 24h
2519last 7d
483● bullish (7d)
258● bearish (7d)
197publishers
AllMacro246Earnings1480M&A141Regulatory16Product4Analyst30
✕ clear all filtersticker: HIMSsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Agilent Technologies Q2 Earnings Call Highlights
MarketBeat69d agoneutral
Agilent Technologies Q2 Earnings Call Highlights

Agilent Technologies (NYSE:A) raised its fiscal 2026 outlook after reporting stronger-than-expected second-quarter results, with management pointing to broad-based demand, instrument replacement momentum, pricing actions and operational gains from its Ignite operating system. CEO Padraig McDonnell

Novo Nordisk A/S Q1 Earnings Call Highlights
MarketBeat84d agoneutral
Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Hims & Hers Health Q1 Earnings Call Highlights
MarketBeat85d agoneutral
Hims & Hers Health Q1 Earnings Call Highlights

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise.
Barrons.com85d agoneutral
Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise.

Shares of Hims & Hers Health sank late Monday after the company underperformed first-quarter earnings and revenue expectations, surprising Wall Street with a quarterly loss. The telehealth provider, which made a name for itself in the business of weight-loss drugs, posted a first-quarter loss of 40 cents a share, compared with profit of 20 cents a share a year ago. Wall Street was looking for a profit of 3 cents a share.